- United States
- /
- Tech Hardware
- /
- NasdaqGM:TACT
This Broker Just Slashed Their TransAct Technologies Incorporated (NASDAQ:TACT) Earnings Forecasts
Today is shaping up negative for TransAct Technologies Incorporated (NASDAQ:TACT) shareholders, with the covering analyst delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) estimates were cut sharply as the analyst factored in the latest outlook for the business, concluding that they were too optimistic previously. Surprisingly the share price has been buoyant, rising 17% to US$3.68 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.
After the downgrade, the consensus from TransAct Technologies's lone analyst is for revenues of US$36m in 2020, which would reflect a concerning 21% decline in sales compared to the last year of performance. After this downgrade, the company is anticipated to report a loss of US$0.44 in 2020, a sharp decline from a profit over the last year. Yet before this consensus update, the analyst had been forecasting revenues of US$48m and losses of US$0.10 per share in 2020. Ergo, there's been a clear change in sentiment, with the analyst administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.
Check out our latest analysis for TransAct Technologies
The consensus price target fell 71% to US$4.00, with the analyst clearly concerned about the company following the weaker revenue and earnings outlook.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the TransAct Technologies's past performance and to peers in the same industry. Over the past five years, revenues have declined around 2.9% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for a 21% decline in revenue next year. Compare this against analyst estimates for companies in the wider industry, which suggest that revenues (in aggregate) are expected to grow 6.6% next year. So while a broad number of companies are forecast to decline, unfortunately TransAct Technologies is expected to see its sales affected worse than other companies in the industry.
The Bottom Line
The most important thing to take away is that the analyst increased their loss per share estimates for this year. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Given the scope of the downgrades, it would not be a surprise to see the market become more wary of the business.
There might be good reason for analyst bearishness towards TransAct Technologies, like its declining profit margins. Learn more, and discover the 4 other warning signs we've identified, for free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

Any moat with an opt-out clause for your competitors is just a fence around your own garden.
Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.
Andrew LeggetGreat earnings season, but are the earnings real?

About NasdaqGM:TACT
TransAct Technologies
Designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally.
Excellent balance sheet and fair value.